SlideShare a Scribd company logo
1 of 34
Epidemiology of  CVD in Diabetes
Cardiovascular Disease and  Type 2 Diabetes:  An Update on Risks and Prevention
[object Object],[object Object],[object Object],These slides are available for download from www.ndei.org
[object Object],[object Object],[object Object],Disclosure
WHO Diabetes Estimates: 2000–2030 Number of Cases (in millions) Region 2000 2030 World > 170 > 363 Developed countries > 55 > 84 Developing countries > 114 > 279 Data adapted from Wild S et al.  Diabetes Care . 2004;27:1047-1053. WHO=World Health Organization.
Type 2 Diabetes in the United States: Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],90% to 95% of cases are type 2 diabetes CDC.  National Diabetes Fact Sheet . www.cdc.gov/diabetes/pubs/general.htm. CDC.  Diabetes: Disabling, Deadly, and on the Rise.  2004. www.cdc.gov/nccdphp/aag/pdf/aag_ddt2004.pdf .
Increasing Prevalence of Obesity* Among US Adults  CDC. www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm. *BMI   30 kg/m 2 .   10%-14%   15%-19%  20%-24%   25% 1994 2002
Increasing Prevalence of Diagnosed Diabetes in US Adults  CDC. www.cdc.gov/diabetes/statistics/prev/state/fig61994and2002.htm. 1994 2002 <4%  4%-4.9%  5%-5.9%   6%
Prevalence of the Metabolic Syndrome* in the US Population *As defined by the National Cholesterol Education  Program. Age adjusted,   20 years of age. White African American Mexican American Other Prevalence (% of adults) 40 35 30 25 20 15 10 5 0 Men Women Ford ES et al.  JAMA . 2002;287:356-359.
Relationship Between Type 2 Diabetes and the Metabolic Syndrome Metabolic Syndrome Type 2 Diabetes Data from Alexander CM et al.  Diabetes . 2003;52:1210-1214.  44% of US adults aged >50 y have the metabolic syndrome (NHANES III) (13% without  metabolic syndrome) 87% of  patients with diabetes have the metabolic syndrome
Risk for Diabetes-Associated Conditions in People Aged <45 Years  ADA.  Diabetes Care . 1998;21:296-309. 11.5 10.3  7.4  5.4 4.8  4.3  2.8 1 5 10 15 CVD PVD Ophthalmic  Neurologic  Other chronic complications Renal  General medical conditions Relative prevalence* Data are odds ratios. *Adjusted for race.
CHD in US Adults >50 Years of Age by Metabolic Syndrome and Diabetes Status Alexander CM et al.  Diabetes . 2003;52:1210-1214. CHD=coronary heart disease. MetS=metabolic syndrome. T2D=type 2 diabetes. % of total  population 54.2 28.7 2.3 14.8 CHD prevalence (%) 0 5 10 15 20 25 No MetS/No T2D T2D/No MetS T2D/MetS 8.7 13.9 7.5 19.2 MetS/No T2D
Complications of Diabetes: Contribution to Excess Healthcare Costs* Other care (59.1%) Acute complications (3.3%) Other vascular  disease (1.3%) Stroke (3.7%) ESRD  (10.6%) Amputation (3.7%) CHD (17.1%) Eye (1.2%) Selby JV et al.  Diabetes Care . 1997;20:1396-1402. Total excess: $282.7 million Contribution of macrovascular complications: 22.1% ($62.5 million) *In a managed care population.
FRISC II: Diabetes Is the Most Important Independent Predictor of Death and MI Norhammar A et al.  J Am Coll Cardiol .   2004;43:585-591. Age Gender Hypertension Diabetes Smoking Previous angina Previous MI ST-depression Troponin T >0.03   g/l 3-VD/LMD 0.98 0.80 1.31 2.40 0.96 1.22 1.85 1.22 1.66 1.06 RR (0.74-1.32) (0.64-0.99) (0.86-2.00) (1.47-3.91) (0.75-1.22) (0.87-1.72) (1.17-2.93) (0.80-1.86) (1.03-2.68) (0.84-1.33) NS 0.039 0.21 0.001 0.73 0.25 0.008 0.348 0.038 0.62 95% CI P 0.5 1 4 RR=risk ratio.
Reported Causes of Death in People With Diabetes Geiss LS et al. In:  Diabetes in America . 2nd ed. 1995; chap 11. Data from death certificates. 0 10 20 30 40 50 Deaths (%) Ischemic heart disease Other heart disease Diabetes Cancer Stroke Infection Other
Mortality in People With Diabetes: Causes of Death ADA.  Summary of the Report and Recommendations of the  Congressionally Established Diabetes Research Working Group, 1999 . 140 120 100 80 60 1980   1984   1988   1992  1996 Year Age-adjusted death rate relative to 1980 Diabetes Cancer CVD Stroke
Mortality Associated With Metabolic Syndrome Data from Lakka H-M et al.  JAMA . 2002;288:2709-2716. Mortality (% of patients) *Adjusted for known CHD risk factors.
Metabolic Syndrome Increases Cardiovascular and Total Mortality Data from Isomaa B et al.  Diabetes Care . 2001;24:683-689. Mortality (%) P <0.001 P <0.001
Mortality Associated With Metabolic Syndrome Malik S et al.  Circulation . 2004;110:1245-1250. Age- and gender-adjusted CHD, CVD, and total mortality rates in US adults with MetS with and without diabetes and pre-existing CVD in the NHANES II Follow-Up Study (n=6,255; mean follow-up, 13.3 years). MetS=metabolic syndrome; T2D=type 2 diabetes. 2.6 5.3 14.4 7.8 17.1 4.8 8.6 21.1 6.3 11.5 26.1 10.9 16.7 30.9 28.1 44.1 4.3 17.0 0 5 10 15 20 25 30 35 40 45 CHD mortality CVD mortality Total mortality Neither MetS nor T2D MetS w/o T2D MetS w/T2D T2D only Prior CVD Prior CVD and T2D Deaths/1,000 person-years
Seven-Year Incidence of Fatal/Nonfatal MI in Finland *No previous myocardial infarction (MI) at baseline. 0 5 10 15 20 25 30 35 40 45 50 7-Year incidence  rate of MI (%) No previous MI* Previous MI No previous MI* Previous MI No diabetes Diabetes (n=1,373) (n=1,059) P <0.001 P <0.001 4 19 20 45 Haffner SM et al.  N Engl J Med.  1998;339:229-234.
OASIS: Cardiovascular Disease Death in Patients With and Without Diabetes Malmberg K et al.  Circulation . 2000;102:1014-1019. *RRs=crude relative risks, adjusted for age and sex (95% CI). OASIS=Organization to Assess  Strategies for Ischemic Syndromes. 3 6 9 12 15 18 21 24 0.20 0.15 0.10 0.05 0.0 Months RR* = 2.85 (2.30-3.53) RR = 1.71 (1.41-2.06) RR = 1.71 (1.25-2.33) RR = 1.00 Diabetes/CVD (n=1,148) Diabetes/no CVD (n=569) No diabetes/CVD (n=3,503) No diabetes/no CVD (n=2,796) Event rate
MRFIT: Impact of Diabetes on  Cardiovascular Disease Mortality Age-adjusted CVD death rate per 10,000 person-years 0 20 40 60 80 100 120 140 No diabetes Diabetes None One only Two only All three Number of risk factors Stamler J et al.  Diabetes Care . 1993;16:434-444. MRFIT=Multiple Risk Factor Intervention Trial.
Risk of Stroke and MI Before and After Type 2 Diabetes Diagnosis No diabetes throughout the study Prior to diagnosis of diabetes After diagnosis of diabetes Diabetes at baseline Relative risk 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1.0 2.82 3.71 5.02 Hu FB et al.  Diabetes Care . 2002;25:1129-1134. MI=myocardial infarction.
Framingham Heart Study: Relative Risk of CVD in Patients With Diabetes Kannel WB et al.  Am Heart J . 1990;120:672-676. * P <0.001;  † P <0.05;  ‡ P <0.01;  § P <0.1. 0 1 2 3 4 5 6 Coronary mortality Sudden death Angina pectoris MI CHD Cardiac failure Intermittent claudication Stroke Any CVD event Age-adjusted risk ratio * § * † * † * † ‡ * † † Men Women ‡ CVD=cardiovascular disease.
Risk Factors for Cardiovascular Disease in Diabetes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Fonseca V et al.  Endocr Rev . 2004;25:153-175.
Components of the Metabolic Syndrome and Incidence of CHD Events 12 10 8 6 4 2 0 0 1 2 3 4 5 Years Patients with CHD event (%)  0 1 2 3 4/5 MetS Components Sattar N et al.  Circulation . 2003;108:414-419. CHD=Coronary heart disease. MetS=metabolic syndrome.
IRAS: Relationship of Insulin Resistance to Atherosclerosis Change in IMT (  m) per 1-unit increase in  S i Howard G et al.  Circulation . 1996;93:1809-1817. P =0.002 P =0.001 P =0.003 P =0.097 P =0.586 P =0.178 IRAS=Insulin Resistance Atherosclerosis Study.  S i =insulin sensitivity.
Paris Prospective Study 10-Year  Follow-up: IGT and Risk of CHD Mortality Eschwège E et al.  Horm Metab Res.  1985;15(suppl):41-46. CHD mortality (incidence  rate/1,000 persons) G<140 mg/dL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],IGT G  200 mg/dL (Newly diagnosed  diabetes) Known diabetes ,[object Object],(6,055) (690) (158) (135) IGT=impaired glucose (G) tolerance.
Impaired Fasting Glucose Increases Risk of Mortality in CHD Patients 0.6 0.7 0.8 0.9 1.0 0 1 2 3 4 5 6 7 8 No diabetes IFG (100  125 mg/dL) Undiagnosed diabetes Actuarial survival Years Fisman EZ et al.  Am Heart J . 2001;141:485-490. * P <0.01 vs no diabetes. † P <0.0001 vs no diabetes. * †
A1C Predicts Coronary Heart Disease in Type 2 Diabetes CHD mortality Incidence in 3.5 years All CHD events Incidence in 3.5 years A1C tertile A1C tertile * P <0.01 vs lowest tertile. † P <0.05 vs lowest tertile. Kuusisto J et al.  Diabetes . 1994;43:960-967. Low <6% Middle 6-7.9% High >7.9% Low <6% Middle 6-7.9% High >7.9% * † % % 0 5 10 15 20 25 0 5 10 15 20 25
A1C Predicts Coronary Heart Disease in Type 2 Diabetes Data from Khaw KT et al.  Ann Intern Med . 2004;141:413-420. CHD events (events/100 persons) A1C concentration *P <0.001 for linear trend  across A1C   categories.
Honolulu Heart Study: High Glucose Postchallenge Increases CHD Donahue RP et al.  Diabetes . 1987;36:689-692. Adjusted for age, center, sex, cholesterol, BMI, SBP, smoking. 0 10 20 30 40 50 60 Fatal CHD Total CHD Postchallenge Glycemic Quintiles 40-114 mg/dL 115-133 mg/dL 134-156 mg/dL 157-189 mg/dL 190-532 mg/dL n=6,394 men without diabetes P <0.001 P <0.01 CHD risk per 1,000 patient-years
DECODE: Risk for All-Cause Mortality Fasting glucose (mg/dL) Hazard ratio Adjusted for age, center, sex, cholesterol, BMI, SBP, smoking. DECODE=Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Adapted from DECODE Study Group.  Lancet . 1999;354:617-621. <110 110-125 126-139  140  200 140-199 <140 2-Hour  OGTT
WESDR: Cause-Specific Mortality in Patients Aged   30 Years With Diabetes Moss SE et al.  Arch Intern Med.  1994;154:2473-2479. *Adjusted for other risk factors, such as smoking and hypertension. WESDR=Wisconsin Epidemiologic Study of Diabetic Retinopathy.  Cause of Death Increase in Hazard Ratio  for Each 1% Increase  in A1C* Ischemic heart disease 10% Stroke 17% Cancer -1%

More Related Content

What's hot

Diabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coinDiabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coinSunil Wadhwa
 
Management of diabetes in heart disease
Management of diabetes  in heart diseaseManagement of diabetes  in heart disease
Management of diabetes in heart diseaseGopi Krishna Rayidi
 
Diabetes and hypertension
Diabetes and hypertensionDiabetes and hypertension
Diabetes and hypertensionjamieleekc
 
Ueda 2016 hypertension &amp; diabetes - gamila nasr
Ueda 2016 hypertension &amp; diabetes -  gamila nasrUeda 2016 hypertension &amp; diabetes -  gamila nasr
Ueda 2016 hypertension &amp; diabetes - gamila nasrueda2015
 
Role of aci ccb in htn management
Role of aci ccb in htn managementRole of aci ccb in htn management
Role of aci ccb in htn managementDr. Adel El Naggar
 
Idf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathyIdf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathyDiabetes for all
 
Diabetic nephropathy management
Diabetic nephropathy managementDiabetic nephropathy management
Diabetic nephropathy managementNaresh Monigari
 
Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Joel Topf
 
International Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesInternational Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesJAFAR ALSAID
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiologyGarima Gupta
 
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. GawadChallenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. GawadNephroTube - Dr.Gawad
 
Pfizer Talk Final
Pfizer Talk FinalPfizer Talk Final
Pfizer Talk Finalhospital
 
Diabetic nephropathy medical management
Diabetic nephropathy   medical managementDiabetic nephropathy   medical management
Diabetic nephropathy medical managementNilesh Jadhav
 
Incidence and Epidemiology of Cardiovascular Disease:
Incidence and Epidemiology of Cardiovascular Disease: Incidence and Epidemiology of Cardiovascular Disease:
Incidence and Epidemiology of Cardiovascular Disease: Doug Levy
 
Diabetic nephropathy why and why not
Diabetic nephropathy why and why notDiabetic nephropathy why and why not
Diabetic nephropathy why and why notalaa wafa
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetesBALASUBRAMANIAM IYER
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Diseasedrsanjaymaitra
 
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...MedicineAndFamily
 

What's hot (20)

Diabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coinDiabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coin
 
Management of diabetes in heart disease
Management of diabetes  in heart diseaseManagement of diabetes  in heart disease
Management of diabetes in heart disease
 
Strive Teleconf Presentation Oct11 2006
Strive Teleconf Presentation Oct11 2006Strive Teleconf Presentation Oct11 2006
Strive Teleconf Presentation Oct11 2006
 
Diabetes and hypertension
Diabetes and hypertensionDiabetes and hypertension
Diabetes and hypertension
 
Ueda 2016 hypertension &amp; diabetes - gamila nasr
Ueda 2016 hypertension &amp; diabetes -  gamila nasrUeda 2016 hypertension &amp; diabetes -  gamila nasr
Ueda 2016 hypertension &amp; diabetes - gamila nasr
 
Role of aci ccb in htn management
Role of aci ccb in htn managementRole of aci ccb in htn management
Role of aci ccb in htn management
 
Idf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathyIdf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathy
 
Diabetic nephropathy management
Diabetic nephropathy managementDiabetic nephropathy management
Diabetic nephropathy management
 
metabolic syndrome review
metabolic syndrome reviewmetabolic syndrome review
metabolic syndrome review
 
Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Diabetic Nephropathy 2009
Diabetic Nephropathy 2009
 
International Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesInternational Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlines
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiology
 
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. GawadChallenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
Challenges in Diagnosis and Management of Diabetic Kidney Disease - Dr. Gawad
 
Pfizer Talk Final
Pfizer Talk FinalPfizer Talk Final
Pfizer Talk Final
 
Diabetic nephropathy medical management
Diabetic nephropathy   medical managementDiabetic nephropathy   medical management
Diabetic nephropathy medical management
 
Incidence and Epidemiology of Cardiovascular Disease:
Incidence and Epidemiology of Cardiovascular Disease: Incidence and Epidemiology of Cardiovascular Disease:
Incidence and Epidemiology of Cardiovascular Disease:
 
Diabetic nephropathy why and why not
Diabetic nephropathy why and why notDiabetic nephropathy why and why not
Diabetic nephropathy why and why not
 
Blood pressure control in diabetes
Blood pressure control in diabetesBlood pressure control in diabetes
Blood pressure control in diabetes
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Disease
 
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... 	 Metabolic Synd...
Metabolic Syndrome, Diabetes, and Cardiovascular Disease ... Metabolic Synd...
 

Viewers also liked

Complications of diabetes melitue
Complications of diabetes melitueComplications of diabetes melitue
Complications of diabetes melitueIzwan Samsi
 
Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus) Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus) Tarek Al 3reeny
 
Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...
Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...
Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...knotcross
 
Cardiovascular disease
Cardiovascular diseaseCardiovascular disease
Cardiovascular diseaseBoss Jake
 
DCCT/EDIC - Type 1 diabetes - cardiovascular risk with intervention
DCCT/EDIC - Type 1 diabetes - cardiovascular risk with interventionDCCT/EDIC - Type 1 diabetes - cardiovascular risk with intervention
DCCT/EDIC - Type 1 diabetes - cardiovascular risk with interventionPeninsulaEndocrine
 
BARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTS
BARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTSBARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTS
BARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTSweightlossindia
 
Journal club.......
Journal club.......Journal club.......
Journal club.......Ramesh Nayak
 
Lifestyle Diseases
Lifestyle DiseasesLifestyle Diseases
Lifestyle Diseasesbdmorin
 
Diabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskDiabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskPrimary Care Diabetes Europe
 
Glp 1 edffect of cardiovascular system
Glp 1 edffect of cardiovascular systemGlp 1 edffect of cardiovascular system
Glp 1 edffect of cardiovascular systemDr. Lin
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyOsama Almaraghi
 
2003 role of incretins in glucose homeostasis and diabetes
2003 role of incretins in glucose homeostasis and diabetes2003 role of incretins in glucose homeostasis and diabetes
2003 role of incretins in glucose homeostasis and diabetesDr.Mudasir Bashir
 

Viewers also liked (16)

Complications of diabetes melitue
Complications of diabetes melitueComplications of diabetes melitue
Complications of diabetes melitue
 
Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus) Managment of Diabesity (Obesity in diabetes mellitus)
Managment of Diabesity (Obesity in diabetes mellitus)
 
Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...
Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...
Diabetes and LDL Cholesterol: 6 Lifestyle Changes to Lower Your LDL Cholester...
 
Cardiovascular disease
Cardiovascular diseaseCardiovascular disease
Cardiovascular disease
 
DCCT/EDIC - Type 1 diabetes - cardiovascular risk with intervention
DCCT/EDIC - Type 1 diabetes - cardiovascular risk with interventionDCCT/EDIC - Type 1 diabetes - cardiovascular risk with intervention
DCCT/EDIC - Type 1 diabetes - cardiovascular risk with intervention
 
Heart Diseases
Heart DiseasesHeart Diseases
Heart Diseases
 
BARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTS
BARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTSBARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTS
BARIATRIC SURGERY IN TREATMENT OF MORBIDLY OBESE PATIENTS
 
DCCT Learned Lessons
DCCT Learned LessonsDCCT Learned Lessons
DCCT Learned Lessons
 
Journal club.......
Journal club.......Journal club.......
Journal club.......
 
Lifestyle Diseases
Lifestyle DiseasesLifestyle Diseases
Lifestyle Diseases
 
Diabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease riskDiabetes Treatment and Cardiovascular Disease risk
Diabetes Treatment and Cardiovascular Disease risk
 
Glp 1 edffect of cardiovascular system
Glp 1 edffect of cardiovascular systemGlp 1 edffect of cardiovascular system
Glp 1 edffect of cardiovascular system
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapy
 
Enrich Programme
Enrich ProgrammeEnrich Programme
Enrich Programme
 
2003 role of incretins in glucose homeostasis and diabetes
2003 role of incretins in glucose homeostasis and diabetes2003 role of incretins in glucose homeostasis and diabetes
2003 role of incretins in glucose homeostasis and diabetes
 
Cardio Vascular Health challenges in presenting century
Cardio Vascular Health challenges in presenting century Cardio Vascular Health challenges in presenting century
Cardio Vascular Health challenges in presenting century
 

Similar to Ndei Cardiovascular Disease In Diabetes Epidemiology

Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...Dr. Jair García-Guerrero
 
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptxUmaShanksr
 
Ueda2015 prevention of cv diseade in dm dr.yehia kishk
Ueda2015 prevention of cv diseade in dm dr.yehia kishkUeda2015 prevention of cv diseade in dm dr.yehia kishk
Ueda2015 prevention of cv diseade in dm dr.yehia kishkueda2015
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...nephro mih
 
DM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdfDM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdfSolidaSakhan
 
Macrovascular disease in diabetes
Macrovascular disease in diabetesMacrovascular disease in diabetes
Macrovascular disease in diabetesPeninsulaEndocrine
 
Case study long standing diabetes
Case study  long standing diabetesCase study  long standing diabetes
Case study long standing diabetesalaa wafa
 
Diabetes lecture
Diabetes lectureDiabetes lecture
Diabetes lectureaswhite
 
Ueda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toonyUeda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toonyueda2015
 
Ueda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toonyUeda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toonyueda2015
 
changing courseoftype2diabetes
changing courseoftype2diabeteschanging courseoftype2diabetes
changing courseoftype2diabetesMunir Ahmad Mughal
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?My Healthy Waist
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...MedicineAndHealthUSA
 
LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”Arindam Pande
 
Diabetic Nephropathy 1
Diabetic Nephropathy 1Diabetic Nephropathy 1
Diabetic Nephropathy 1mondy19
 
Abbotsford feb 26 2014
Abbotsford feb 26 2014Abbotsford feb 26 2014
Abbotsford feb 26 2014Ihsaan Peer
 
new_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.pptnew_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.pptMsccMohamed
 

Similar to Ndei Cardiovascular Disease In Diabetes Epidemiology (20)

Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
Epidemiología de la Resistencia a la Insulina, Diabetes Mellitus y Enfermedad...
 
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
89924635769883821147500-PACE-CME-ACROSS-T2D-Module-A-11Aug2015-000418.pptx
 
Ueda2015 prevention of cv diseade in dm dr.yehia kishk
Ueda2015 prevention of cv diseade in dm dr.yehia kishkUeda2015 prevention of cv diseade in dm dr.yehia kishk
Ueda2015 prevention of cv diseade in dm dr.yehia kishk
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...
 
DM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdfDM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdf
 
The Science Diabetes Control
The Science Diabetes ControlThe Science Diabetes Control
The Science Diabetes Control
 
Macrovascular disease in diabetes
Macrovascular disease in diabetesMacrovascular disease in diabetes
Macrovascular disease in diabetes
 
Case study long standing diabetes
Case study  long standing diabetesCase study  long standing diabetes
Case study long standing diabetes
 
Diabetes lecture
Diabetes lectureDiabetes lecture
Diabetes lecture
 
Ueda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toonyUeda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toony
 
Ueda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toonyUeda2015 diabetes control dr.lobna el-toony
Ueda2015 diabetes control dr.lobna el-toony
 
changing courseoftype2diabetes
changing courseoftype2diabeteschanging courseoftype2diabetes
changing courseoftype2diabetes
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
 
Type 2 DM ; Metformin Best Partner
Type 2 DM ; Metformin Best PartnerType 2 DM ; Metformin Best Partner
Type 2 DM ; Metformin Best Partner
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
 
LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”LDL Cholesterol Target :“ Lower the Better ”
LDL Cholesterol Target :“ Lower the Better ”
 
epidemilogy of diabetes
epidemilogy of diabetesepidemilogy of diabetes
epidemilogy of diabetes
 
Diabetic Nephropathy 1
Diabetic Nephropathy 1Diabetic Nephropathy 1
Diabetic Nephropathy 1
 
Abbotsford feb 26 2014
Abbotsford feb 26 2014Abbotsford feb 26 2014
Abbotsford feb 26 2014
 
new_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.pptnew_insulins_and_insulin_delivery_systems_part_1.ppt
new_insulins_and_insulin_delivery_systems_part_1.ppt
 

Recently uploaded

L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxDr Bilal Natiq
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Monoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyMonoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyHasnat Tariq
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 

Recently uploaded (20)

L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Monoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technologyMonoclonal antibody production by hybridoma technology
Monoclonal antibody production by hybridoma technology
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 

Ndei Cardiovascular Disease In Diabetes Epidemiology

  • 1. Epidemiology of CVD in Diabetes
  • 2. Cardiovascular Disease and Type 2 Diabetes: An Update on Risks and Prevention
  • 3.
  • 4.
  • 5. WHO Diabetes Estimates: 2000–2030 Number of Cases (in millions) Region 2000 2030 World > 170 > 363 Developed countries > 55 > 84 Developing countries > 114 > 279 Data adapted from Wild S et al. Diabetes Care . 2004;27:1047-1053. WHO=World Health Organization.
  • 6.
  • 7. Increasing Prevalence of Obesity* Among US Adults CDC. www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm. *BMI  30 kg/m 2 . 10%-14% 15%-19% 20%-24%  25% 1994 2002
  • 8. Increasing Prevalence of Diagnosed Diabetes in US Adults CDC. www.cdc.gov/diabetes/statistics/prev/state/fig61994and2002.htm. 1994 2002 <4% 4%-4.9% 5%-5.9%  6%
  • 9. Prevalence of the Metabolic Syndrome* in the US Population *As defined by the National Cholesterol Education Program. Age adjusted,  20 years of age. White African American Mexican American Other Prevalence (% of adults) 40 35 30 25 20 15 10 5 0 Men Women Ford ES et al. JAMA . 2002;287:356-359.
  • 10. Relationship Between Type 2 Diabetes and the Metabolic Syndrome Metabolic Syndrome Type 2 Diabetes Data from Alexander CM et al. Diabetes . 2003;52:1210-1214.  44% of US adults aged >50 y have the metabolic syndrome (NHANES III) (13% without metabolic syndrome) 87% of patients with diabetes have the metabolic syndrome
  • 11. Risk for Diabetes-Associated Conditions in People Aged <45 Years ADA. Diabetes Care . 1998;21:296-309. 11.5 10.3 7.4 5.4 4.8 4.3 2.8 1 5 10 15 CVD PVD Ophthalmic Neurologic Other chronic complications Renal General medical conditions Relative prevalence* Data are odds ratios. *Adjusted for race.
  • 12. CHD in US Adults >50 Years of Age by Metabolic Syndrome and Diabetes Status Alexander CM et al. Diabetes . 2003;52:1210-1214. CHD=coronary heart disease. MetS=metabolic syndrome. T2D=type 2 diabetes. % of total population 54.2 28.7 2.3 14.8 CHD prevalence (%) 0 5 10 15 20 25 No MetS/No T2D T2D/No MetS T2D/MetS 8.7 13.9 7.5 19.2 MetS/No T2D
  • 13. Complications of Diabetes: Contribution to Excess Healthcare Costs* Other care (59.1%) Acute complications (3.3%) Other vascular disease (1.3%) Stroke (3.7%) ESRD (10.6%) Amputation (3.7%) CHD (17.1%) Eye (1.2%) Selby JV et al. Diabetes Care . 1997;20:1396-1402. Total excess: $282.7 million Contribution of macrovascular complications: 22.1% ($62.5 million) *In a managed care population.
  • 14. FRISC II: Diabetes Is the Most Important Independent Predictor of Death and MI Norhammar A et al. J Am Coll Cardiol . 2004;43:585-591. Age Gender Hypertension Diabetes Smoking Previous angina Previous MI ST-depression Troponin T >0.03  g/l 3-VD/LMD 0.98 0.80 1.31 2.40 0.96 1.22 1.85 1.22 1.66 1.06 RR (0.74-1.32) (0.64-0.99) (0.86-2.00) (1.47-3.91) (0.75-1.22) (0.87-1.72) (1.17-2.93) (0.80-1.86) (1.03-2.68) (0.84-1.33) NS 0.039 0.21 0.001 0.73 0.25 0.008 0.348 0.038 0.62 95% CI P 0.5 1 4 RR=risk ratio.
  • 15. Reported Causes of Death in People With Diabetes Geiss LS et al. In: Diabetes in America . 2nd ed. 1995; chap 11. Data from death certificates. 0 10 20 30 40 50 Deaths (%) Ischemic heart disease Other heart disease Diabetes Cancer Stroke Infection Other
  • 16. Mortality in People With Diabetes: Causes of Death ADA. Summary of the Report and Recommendations of the Congressionally Established Diabetes Research Working Group, 1999 . 140 120 100 80 60 1980 1984 1988 1992 1996 Year Age-adjusted death rate relative to 1980 Diabetes Cancer CVD Stroke
  • 17. Mortality Associated With Metabolic Syndrome Data from Lakka H-M et al. JAMA . 2002;288:2709-2716. Mortality (% of patients) *Adjusted for known CHD risk factors.
  • 18. Metabolic Syndrome Increases Cardiovascular and Total Mortality Data from Isomaa B et al. Diabetes Care . 2001;24:683-689. Mortality (%) P <0.001 P <0.001
  • 19. Mortality Associated With Metabolic Syndrome Malik S et al. Circulation . 2004;110:1245-1250. Age- and gender-adjusted CHD, CVD, and total mortality rates in US adults with MetS with and without diabetes and pre-existing CVD in the NHANES II Follow-Up Study (n=6,255; mean follow-up, 13.3 years). MetS=metabolic syndrome; T2D=type 2 diabetes. 2.6 5.3 14.4 7.8 17.1 4.8 8.6 21.1 6.3 11.5 26.1 10.9 16.7 30.9 28.1 44.1 4.3 17.0 0 5 10 15 20 25 30 35 40 45 CHD mortality CVD mortality Total mortality Neither MetS nor T2D MetS w/o T2D MetS w/T2D T2D only Prior CVD Prior CVD and T2D Deaths/1,000 person-years
  • 20. Seven-Year Incidence of Fatal/Nonfatal MI in Finland *No previous myocardial infarction (MI) at baseline. 0 5 10 15 20 25 30 35 40 45 50 7-Year incidence rate of MI (%) No previous MI* Previous MI No previous MI* Previous MI No diabetes Diabetes (n=1,373) (n=1,059) P <0.001 P <0.001 4 19 20 45 Haffner SM et al. N Engl J Med. 1998;339:229-234.
  • 21. OASIS: Cardiovascular Disease Death in Patients With and Without Diabetes Malmberg K et al. Circulation . 2000;102:1014-1019. *RRs=crude relative risks, adjusted for age and sex (95% CI). OASIS=Organization to Assess Strategies for Ischemic Syndromes. 3 6 9 12 15 18 21 24 0.20 0.15 0.10 0.05 0.0 Months RR* = 2.85 (2.30-3.53) RR = 1.71 (1.41-2.06) RR = 1.71 (1.25-2.33) RR = 1.00 Diabetes/CVD (n=1,148) Diabetes/no CVD (n=569) No diabetes/CVD (n=3,503) No diabetes/no CVD (n=2,796) Event rate
  • 22. MRFIT: Impact of Diabetes on Cardiovascular Disease Mortality Age-adjusted CVD death rate per 10,000 person-years 0 20 40 60 80 100 120 140 No diabetes Diabetes None One only Two only All three Number of risk factors Stamler J et al. Diabetes Care . 1993;16:434-444. MRFIT=Multiple Risk Factor Intervention Trial.
  • 23. Risk of Stroke and MI Before and After Type 2 Diabetes Diagnosis No diabetes throughout the study Prior to diagnosis of diabetes After diagnosis of diabetes Diabetes at baseline Relative risk 0.0 1.0 2.0 3.0 4.0 5.0 6.0 1.0 2.82 3.71 5.02 Hu FB et al. Diabetes Care . 2002;25:1129-1134. MI=myocardial infarction.
  • 24. Framingham Heart Study: Relative Risk of CVD in Patients With Diabetes Kannel WB et al. Am Heart J . 1990;120:672-676. * P <0.001; † P <0.05; ‡ P <0.01; § P <0.1. 0 1 2 3 4 5 6 Coronary mortality Sudden death Angina pectoris MI CHD Cardiac failure Intermittent claudication Stroke Any CVD event Age-adjusted risk ratio * § * † * † * † ‡ * † † Men Women ‡ CVD=cardiovascular disease.
  • 25.
  • 26. Components of the Metabolic Syndrome and Incidence of CHD Events 12 10 8 6 4 2 0 0 1 2 3 4 5 Years Patients with CHD event (%) 0 1 2 3 4/5 MetS Components Sattar N et al. Circulation . 2003;108:414-419. CHD=Coronary heart disease. MetS=metabolic syndrome.
  • 27. IRAS: Relationship of Insulin Resistance to Atherosclerosis Change in IMT (  m) per 1-unit increase in S i Howard G et al. Circulation . 1996;93:1809-1817. P =0.002 P =0.001 P =0.003 P =0.097 P =0.586 P =0.178 IRAS=Insulin Resistance Atherosclerosis Study. S i =insulin sensitivity.
  • 28.
  • 29. Impaired Fasting Glucose Increases Risk of Mortality in CHD Patients 0.6 0.7 0.8 0.9 1.0 0 1 2 3 4 5 6 7 8 No diabetes IFG (100  125 mg/dL) Undiagnosed diabetes Actuarial survival Years Fisman EZ et al. Am Heart J . 2001;141:485-490. * P <0.01 vs no diabetes. † P <0.0001 vs no diabetes. * †
  • 30. A1C Predicts Coronary Heart Disease in Type 2 Diabetes CHD mortality Incidence in 3.5 years All CHD events Incidence in 3.5 years A1C tertile A1C tertile * P <0.01 vs lowest tertile. † P <0.05 vs lowest tertile. Kuusisto J et al. Diabetes . 1994;43:960-967. Low <6% Middle 6-7.9% High >7.9% Low <6% Middle 6-7.9% High >7.9% * † % % 0 5 10 15 20 25 0 5 10 15 20 25
  • 31. A1C Predicts Coronary Heart Disease in Type 2 Diabetes Data from Khaw KT et al. Ann Intern Med . 2004;141:413-420. CHD events (events/100 persons) A1C concentration *P <0.001 for linear trend across A1C categories.
  • 32. Honolulu Heart Study: High Glucose Postchallenge Increases CHD Donahue RP et al. Diabetes . 1987;36:689-692. Adjusted for age, center, sex, cholesterol, BMI, SBP, smoking. 0 10 20 30 40 50 60 Fatal CHD Total CHD Postchallenge Glycemic Quintiles 40-114 mg/dL 115-133 mg/dL 134-156 mg/dL 157-189 mg/dL 190-532 mg/dL n=6,394 men without diabetes P <0.001 P <0.01 CHD risk per 1,000 patient-years
  • 33. DECODE: Risk for All-Cause Mortality Fasting glucose (mg/dL) Hazard ratio Adjusted for age, center, sex, cholesterol, BMI, SBP, smoking. DECODE=Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Adapted from DECODE Study Group. Lancet . 1999;354:617-621. <110 110-125 126-139  140  200 140-199 <140 2-Hour OGTT
  • 34. WESDR: Cause-Specific Mortality in Patients Aged  30 Years With Diabetes Moss SE et al. Arch Intern Med. 1994;154:2473-2479. *Adjusted for other risk factors, such as smoking and hypertension. WESDR=Wisconsin Epidemiologic Study of Diabetic Retinopathy. Cause of Death Increase in Hazard Ratio for Each 1% Increase in A1C* Ischemic heart disease 10% Stroke 17% Cancer -1%